BDH2 Inhibits Lung Adenocarcinoma Metastasis by Promoting Ferroptosis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality.
• Metastasis remains a major challenge in LUAD treatment.
• The role of ferroptosis regulation in LUAD metastasis is an area of active investigation.

Purpose of the Study:

• To elucidate the function of 3-hydroxybutyrate dehydrogenase 2 (BDH2) in ferroptosis.
• To determine the impact of BDH2 on lung adenocarcinoma (LUAD) cell metastasis.
• To investigate the underlying molecular mechanisms involving the Nrf2/HO-1 signaling pathway.

Main Methods:

• Modulation of BDH2 expression in LUAD cell lines (A549, PC9).
• Assessment of cell migration, invasion, and ferroptosis markers (Fe2+, MDA, lipid ROS, ACSL4, GPX4).
• Analysis of Nrf2/HO-1 pathway activation and in vivo xenograft mouse models.

Main Results:

• BDH2 overexpression inhibited LUAD cell migration and invasion.
• Upregulation of BDH2 enhanced ferroptosis, which was reversible by Fer-1.
• BDH2 suppressed Nrf2/HO-1 pathway activation, increasing ferroptosis sensitivity.
• In vivo studies showed reduced tumor growth and metastasis with BDH2 overexpression.

Conclusions:

• BDH2 suppresses LUAD metastasis by promoting ferroptosis via inhibition of the Nrf2/HO-1 pathway.
• BDH2 acts as a tumor suppressor in LUAD progression and metastasis.
• BDH2 represents a potential therapeutic target for treating LUAD metastasis.